Abstract：
In accordance with the recommendations of, among others, the Surviving Sepsis Campaign, adjunctive therapies may play a role in the treatment and the prognosis in sepsis patients. Corticosteroids, ascorbic acid, and thiamine has been identified as a potential therapy for septic shock alone or in combination. Since many years, low-dosis corticosteroids has been proposed as adjuvant therapies for these patients. However, there are still many controversies regarding the role of systemic low-dose corticosteroids as a part of the treatment of septic shock. In recent clinical and experimental investigations, mitochondrion-target therapy bic acid and thiamine) for sepsis has been suggested to reduce MODS severity and mortality although their clinical results are not yet convincing for their use. In the present article, we have performed a narrative review of the current literature including pathophysiologic rationale and the current evidence for such therapies in septic patients.
摘要：
根据的建议，其中,幸存的败血症运动，辅助治疗可能在脓毒症患者的治疗和预后中起作用。皮质类固醇,抗坏血酸,和硫胺素已被确定为单独或联合治疗感染性休克的潜在疗法。多年以来,低剂量糖皮质激素已被提议作为这些患者的辅助治疗。然而,关于全身性低剂量糖皮质激素作为感染性休克治疗的一部分的作用,仍存在许多争议.在最近的临床和实验研究中，线粒体靶向疗法，维生素酸和硫胺素）用于脓毒症已被认为可以降低MODS的严重程度和死亡率，尽管其临床结果尚不能令人信服。在本文中,我们对目前的文献进行了叙述性回顾,包括在脓毒症患者中进行此类治疗的病理生理学原理和目前的证据.
